OrthoPediatrics (KIDS) reported earnings on Tue 27 Oct 26 (a/h)

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 602
• Founded by Erin Springer Yount and Nick A. Deeter in 2006 
• Headquartered in Warsaw, Indiana
• https://www.orthopediatrics.com

IPO Key Details

• IPO Date: October 12, 2017

• Offer Price: $13.00 per share

 

 

 

OrthoPediatrics posts record Q3 2026 revenue $72.7M (+19% YoY), raises 2026 revenue outlook to $270–$273M

• Record Q3 revenue $72.7M, +19% YoY, driven by implants and OPSB growth.
• GAAP EPS loss improved to -$0.25 versus -$0.50 last year.
• Q3 2026 non-GAAP EPS was -$0.23, an improvement of 4% year over year.
• Company missed Q3 2026 EPS estimates but exceeded revenue estimates.
• Adjusted EBITDA reached record $6.9M, ~10% margin, reflecting strong operating leverage.
• Gross margin steady at 74% despite mix shift toward lower-margin but accretive OPSB.
• Free cash flow positive $1.6M versus -$3.4M prior year, guidance reiterated.
• 2026 revenue outlook raised to $270–$273M from $265–$269M, 14–16% growth; EBITDA ~$25M maintained.
• OPSB bracing grew above 20%, now over 60 clinics and 34 systems.
• International revenue rose 18% to $14.8M, led by EMEA; LatAm constrained by set discipline.
• Super Cycle products early but ramping, with major contributions expected in 2027 and beyond.
• Main risks include clinic expansion costs, Brazil/LatAm set pullback, and lumpy 7D and set sales.
• Main concern is sustainability of growth and margin expansion amid clinic investments and cautious LatAm deployment.

Summit Midstream Corporation (SMC)

Summit Midstream Partners, LP priced its initial public offering (IPO) of 12.5 million common shares at $20.00 per share on September 27, 2012, and began trading on the New York Stock Exchange under the ticker symbol SMLP, later transitioning its corporate structure to Summit Midstream Corporation (NYSE: SMC). 

• Sector: Energy
• Industry: Oil & Gas Midstream
• Headquarters: Houston, Texas
• Full Time Employees: 296
• Current Ticker/Structure: SMC (Summit Midstream Corporation) following its corporate conversion to a C-corporation
• https://www.summitmidstream.com

 

 

==Pacira BioSciences (PCRX) to be acquired by Viatris (VTRS) for $36.50/share cash

Viatris agreed to buy all outstanding Pacira shares for $36.50 each in cash, valuing Pacira's equity at about $1.65 bln.

• Pacira adds marketed non-opioid pain products EXPAREL and ZILRETTA; the company generated about $746 mln of revenue and $177 mln of adjusted EBITDA in the last 12 months ended June 30, 2026.
• Viatris said the deal should expand its U.S. innovative medicines capabilities, be synergistic with its fast-acting meloxicam opportunity, and be immediately accretive to financial guidance metrics.
• The transaction is expected to close by the end of 2026 and Viatris said it preserves financial flexibility under its capital allocation strategy.